Last edition
News about Drug Discovery & Development
Roche Receives CE Mark for Elecsys Dengue Antigen Test, Enhancing Global Diagnostic Capabilities
This milestone represents a significant advancement in efficiency and reliability for laboratories worldwide, helping healthcare systems address the escalating global dengue crisis.
Drug Discovery & Development | 30/10/2025 | By Darshana | 190
CEPI, SII and Oxford University Collaborate to Develop Nipah Virus Vaccine Reserve
CEPI, the Serum Institute of India, and the University of Oxford have partnered to produce ChAdOx1 NipahB vaccine doses for Phase II trials and an investigational reserve of up to 100,000 doses, ready for rapid deployment in case of a future Nipah outbreak.
Drug Discovery & Development | 30/10/2025 | By Dineshwori | 157
Biogen licences Vanqua Bio's immune-disorder drug in deal worth up to USD 1.06 billion
Biogen has entered into an agreement with Vanqua Bio to acquire global rights to an experimental oral therapy for immune-related disorders, in a deal valued at up to USD 1.06 billion.
Drug Discovery & Development | 27/10/2025 | By Darshana | 131
With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing – placing it among a handful of CDMOs with full-service capabilities.
Drug Discovery & Development | 24/10/2025 | By Darshana | 116
Danish drugmaker Novo Nordisk has entered into a definitive asset purchase and license agreement with US-based Omeros Corporation for zaltenibart (formerly OMS906), a clinical-stage antibody therapy being developed for rare blood and kidney disorders.
Drug Discovery & Development | 16/10/2025 | By Dineshwori | 144
EG BioMed Earns CAP Accreditation, Boosting YD Bio's Cancer Diagnostics
EG BioMed is one of YD Bio’s key licensing partners for pancreatic and breast cancer detection and collaborates with 3D Global to develop treatments for eye disorders.
Drug Discovery & Development | 13/10/2025 | By Darshana | 129
India’s small and mid-sized pharmaceutical manufacturers are raising alarms over new good manufacturing practice (GMP) and bio-equivalence mandates, warning that the regulations could widen the gap between large companies and micro, small, and medium enterprises (MSMEs).
Drug Discovery & Development | 13/10/2025 | By Darshana | 371
Zenas BioPharma Signs USD 2 Billion Licensing Deal with InnoCare for Autoimmune Drugs
Zenas BioPharma has entered into a licensing agreement with China’s InnoCare Pharma worth up to USD 2 billion to develop and commercialise three autoimmune drug candidates, including a late-stage treatment for multiple sclerosis.
Drug Discovery & Development | 09/10/2025 | By Darshana | 234
Through the partnership among Sai Life Sciences, Agility Life Sciences and Centrix Pharma Solutions, customers will have access to integrated drug substance and drug product development, helping them move efficiently from pre-clinical studies to First-In-Human (FIH) clinical trials and beyond.
Drug Discovery & Development | 09/10/2025 | By Dineshwori
BD and Opentrons Collaborate to Automate Single-Cell Multiomics Workflows
BD (Becton, Dickinson and Company) and Opentrons Labworks, Inc. have entered into a multi-year collaboration to accelerate advances in single-cell multiomics research by integrating robotic automation into critical laboratory workflows.
Drug Discovery & Development | 08/10/2025 | By Darshana | 304
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy